胰高血糖素样肽-1（GLP-1）受体激动剂和葡萄糖依赖性促胰岛素多肽（GIP）受体激动剂在阻塞性睡眠呼吸暂停和肥胖中的潜在作用
The Potential Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonists in Obstructive Sleep Apnea and Obesity.
作者信息
Ellberg Charlotte C, Schwartz Hannah, Witt Annika, McCowen Karen C, Fuentes Ana Lucia, Malhotra Atul
机构信息
Department of Medicine, University of California, San Diego, La Jolla, CA USA.
Department of Medicine, Weill Cornell Medicine, New York, NY USA.
出版信息
Curr Pulmonol Rep. 2025;14(1):19. doi: 10.1007/s13665-025-00384-1. Epub 2025 Jul 25.
Abstract
PURPOSE OF REVIEW
Strong associations exist between obstructive sleep apnea (OSA) and obesity. Prior studies have demonstrated that weight reduction in people with OSA and obesity improves severity of OSA. Until recently, there were no approved pharmacotherapies for OSA. We aim to review recent literature on GLP-1 receptor agonists and GIP agonists and their potential role in the management of OSA.
RECENT FINDINGS
Novel pharmacotherapies developed to target obesity include glucagon-like peptide-1 (GLP-1) receptor agonists and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists. These therapies have proven to be helpful in many comorbid conditions, with published studies suggesting a benefit in OSA.
SUMMARY
GLP-1 receptor agonists and GIP agonists are emerging potential therapies for OSA and associated cardiometabolic risk.
摘要
综述目的
阻塞性睡眠呼吸暂停（OSA）与肥胖之间存在密切关联。先前的研究表明，OSA合并肥胖者体重减轻可改善OSA的严重程度。直到最近，尚无获批用于治疗OSA的药物疗法。我们旨在综述有关胰高血糖素样肽-1（GLP-1）受体激动剂和葡萄糖依赖性促胰岛素多肽（GIP）受体激动剂及其在OSA管理中的潜在作用的最新文献。
最新发现
针对肥胖开发的新型药物疗法包括GLP-1受体激动剂和GIP受体激动剂。这些疗法已被证明对许多合并症有帮助，已发表的研究表明对OSA有益。
总结
GLP-1受体激动剂和GIP受体激动剂正在成为治疗OSA及相关心脏代谢风险的潜在疗法。
相似文献
1
The Potential Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonists in Obstructive Sleep Apnea and Obesity.胰高血糖素样肽-1（GLP-1）受体激动剂和葡萄糖依赖性促胰岛素多肽（GIP）受体激动剂在阻塞性睡眠呼吸暂停和肥胖中的潜在作用
Curr Pulmonol Rep. 2025;14(1):19. doi: 10.1007/s13665-025-00384-1. Epub 2025 Jul 25.
2
Efficacy of incretin-based therapies in obesity-related obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trials.基于肠促胰岛素的疗法在肥胖相关阻塞性睡眠呼吸暂停中的疗效：一项随机对照试验的系统评价和荟萃分析
Sleep Med Rev. 2025 Aug;82:102119. doi: 10.1016/j.smrv.2025.102119. Epub 2025 Jun 17.
3
Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data.用于心脏保护、2型糖尿病和肥胖症的胰高血糖素样肽-1/葡萄糖依赖性促胰岛素多肽受体共同激动剂：作用机制及临床数据综述
Curr Opin Cardiol. 2023 Nov 1;38(6):539-545. doi: 10.1097/HCO.0000000000001084. Epub 2023 Aug 21.
4
Review Article: GLP-1 Receptor Agonists and Glucagon/GIP/GLP-1 Receptor Dual or Triple Agonists-Mechanism of Action and Emerging Therapeutic Landscape in MASLD.综述文章：胰高血糖素样肽-1受体激动剂以及胰高血糖素/葡萄糖依赖性促胰岛素多肽/胰高血糖素样肽-1受体双重或三重激动剂——非酒精性脂肪性肝炎的作用机制及新兴治疗前景
Aliment Pharmacol Ther. 2025 Jun;61(12):1872-1888. doi: 10.1111/apt.70196. Epub 2025 May 13.
5
The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.评估胰高血糖素样肽-1受体激动剂（GLP-1 RAs）减肥效果的网状Meta分析的数量、质量及结果：一项范围综述
Health Technol Assess. 2025 Jun 25:1-73. doi: 10.3310/SKHT8119.
6
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.使用双重 GIP/GLP-1 受体激动剂替西帕肽治疗 2 型糖尿病：系统评价和荟萃分析。
Diabetologia. 2022 Aug;65(8):1251-1261. doi: 10.1007/s00125-022-05715-4. Epub 2022 May 17.
7
Triple Agonism Based Therapies for Obesity.基于三重激动作用的肥胖症治疗方法
Curr Cardiovasc Risk Rep. 2025;19(1):18. doi: 10.1007/s12170-025-00770-z. Epub 2025 Jul 28.
8
Implications of GLP-1 Agonists on Office-Based Sedation and General Anesthesia for Dentistry.胰高血糖素样肽-1激动剂对牙科门诊镇静和全身麻醉的影响。
Anesth Prog. 2025 Mar 12;72(1):52-58. doi: 10.2344/anpr-72-1-ANPR_Agonists.
9
Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.用于慢性肾病和糖尿病患者的胰高血糖素样肽1（GLP-1）受体激动剂。
Cochrane Database Syst Rev. 2025 Feb 18;2(2):CD015849. doi: 10.1002/14651858.CD015849.pub2.
10
Comparative Efficacy of Tirzepatide, Liraglutide, and Semaglutide in Reduction of Risk of Major Adverse Cardiovascular Events in Patients with Obstructive Sleep Apnea and Type 2 Diabetes: Real-World Evidence.替尔泊肽、利拉鲁肽和司美格鲁肽在降低阻塞性睡眠呼吸暂停合并2型糖尿病患者主要不良心血管事件风险方面的疗效比较：真实世界证据
Ann Am Thorac Soc. 2025 Jul;22(7):1042-1052. doi: 10.1513/AnnalsATS.202409-923OC.
本文引用的文献
1
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.替尔泊肽与司美格鲁肽治疗肥胖症的比较
N Engl J Med. 2025 Jul 3;393(1):26-36. doi: 10.1056/NEJMoa2416394. Epub 2025 May 11.
2
The relationship between obesity and obstructive sleep apnea in four community-based cohorts: an individual participant data meta-analysis of 12,860 adults.四个社区队列中肥胖与阻塞性睡眠呼吸暂停之间的关系：一项对12860名成年人的个体参与者数据荟萃分析
EClinicalMedicine. 2025 Apr 23;83:103221. doi: 10.1016/j.eclinm.2025.103221. eCollection 2025 May.
3
Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial.替尔泊肽与2型糖尿病患者肌肉成分变化（SURPASS-3 MRI）：一项随机、开放标签、平行组3期试验的事后分析
Lancet Diabetes Endocrinol. 2025 Jun;13(6):482-493. doi: 10.1016/S2213-8587(25)00027-0. Epub 2025 Apr 30.
4
GIPR-Ab/GLP-1 peptide-antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice.GIPR抗体/GLP-1肽-抗体偶联物在肥胖小鼠中实现额外体重减轻需要脑GIPR和GLP-1R。
Nat Metab. 2025 Apr 29. doi: 10.1038/s42255-025-01295-w.
5
An inhibitory GLP-1 circuit in the lateral septum modulates reward processing and alcohol intake in rodents.外侧隔区中的抑制性胰高血糖素样肽-1回路调节啮齿动物的奖赏处理和酒精摄入。
EBioMedicine. 2025 May;115:105684. doi: 10.1016/j.ebiom.2025.105684. Epub 2025 Apr 17.
6
The impact of a selective androgen receptor modulator (RAD140) on frailty and underlying mechanisms in older male and female C57Bl/6 mice.选择性雄激素受体调节剂（RAD140）对老年雄性和雌性C57Bl/6小鼠虚弱状况及潜在机制的影响
Mech Ageing Dev. 2025 Jun;225:112054. doi: 10.1016/j.mad.2025.112054. Epub 2025 Mar 28.
7
Positive airway pressure therapy and all-cause and cardiovascular mortality in people with obstructive sleep apnoea: a systematic review and meta-analysis of randomised controlled trials and confounder-adjusted, non-randomised controlled studies.持续气道正压通气治疗与阻塞性睡眠呼吸暂停患者的全因死亡率和心血管死亡率：一项对随机对照试验以及经混杂因素调整的非随机对照研究的系统评价和荟萃分析
Lancet Respir Med. 2025 May;13(5):403-413. doi: 10.1016/S2213-2600(25)00002-5. Epub 2025 Mar 18.
8
Treatable Traits-Based Pharmacologic Treatment of Sleep Apnea.基于可治疗特征的睡眠呼吸暂停药物治疗
Sleep Med Clin. 2025 Mar;20(1):103-114. doi: 10.1016/j.jsmc.2024.10.002. Epub 2024 Dec 10.
9
Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions.评估基于肠促胰岛素的肥胖治疗药物对各种慢性疾病的直接组织效应与体重减轻效应。
Lancet Diabetes Endocrinol. 2025 Apr;13(4):347-354. doi: 10.1016/S2213-8587(24)00363-2. Epub 2025 Jan 24.
10
Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea: a meta-analysis.用于治疗阻塞性睡眠呼吸暂停的胰高血糖素样肽-1受体激动剂：一项荟萃分析。
Sleep. 2025 Apr 11;48(4). doi: 10.1093/sleep/zsae280.
Zotero 插件